Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.73 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.59 |
| ▸ | ITGAL | P20701 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Nitro-Cinnamic Acid SCHEMBL426380 | 1.00 | MAPT (0.73) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL448381 | 1.00 | MAPT (0.73) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL29626695 | 1.00 | MAPT (0.73) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL4179178 | 1.00 | MAPT (0.73) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL7990710 | 0.98 | MAPT (0.71) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL27877632 | 0.98 | MAPT (0.71) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL7401665 | 0.98 | MAPT (0.71) | MAPTMAOBNFE2L2FBP1VCP | |
| 3-Nitro-Cinnamic Acid SCHEMBL7990708 | 0.97 | MAPT (0.69) | MAPTMAOBNFE2L2FBP1VCP | |
| SCHEMBL5209312 | 0.91 | MAPT (0.62) | MAPTMAOBNFE2L2FBP1VCP | |
| SCHEMBL5209309 | 0.91 | MAPT (0.62) | MAPTMAOBNFE2L2FBP1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256459-A1 | NOVEL PROCESS FOR THE PREPARATION OF BELINOSTAT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2019-08-22 | — | — | US | claimed |
| WO-2017199264-A1 | NOVEL PROCESS FOR THE PREPARATION OF BELINOSTAT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-11-23 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190256459-A1 | NOVEL PROCESS FOR THE PREPARATION OF BELINOSTAT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2019-08-22 | — | — | US | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
| US-5539074-A | LIQUID CRYSTAL POLYMERS ON SILICA FOR LIGHT SENSITIVE ELEMENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885MAOB 3732/4885NFE2L2 2167/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885MAOB 3732/4885NFE2L2 2167/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | MAPT 4074/4885MAOB 62/4885NFE2L2 1266/4885 |
| US-20190256459-A1 | NOVEL PROCESS FOR THE PREPARATION OF BELINOSTAT | ACR, AADAC, CDK11A | MAPT 3904/4885MAOB 3164/4885NFE2L2 4402/4885 |
| US-10703712-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885MAOB 3732/4885NFE2L2 2167/4885 |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | MAPT 4394/4885MAOB 3732/4885NFE2L2 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.